Drug Trial Radar · NCT04619797
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
542
Actual
Start
Dec 15, 2020
Primary completion
Apr 19, 2024
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during the induction phase: * Arm A: Tiragolumab plus atezolizumab plus pemetrexed and carboplatin or cisplatin * Arm B: Placebo plus pembrolizumab plus pemetrexed and carboplatin or cisplatin Following the induction phase, participants will continue maintenance therapy with either tiragolumab in combination with atezolizumab and pemetrexed (Arm A) or placebo in combination with pembrolizumab and pemetrexed (Arm B).
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
TiragolumabDrug
Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
AtezolizumabDrug
Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
PemetrexedDrug
Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
CarboplatinDrug
Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
CisplatinDrug
Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
Tiragolumab Matching PlaceboDrug
Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
PembrolizumabDrug
Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Determined by the InvestigatorTime frame: From randomization to first occurrence of PD or death from any cause (up to approximately 40 months)
- Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 40 months)
Locations
127 sites in 21 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
PIH Health Whittier Hospital
Whittier, California
SCRI Florida Cancer Specialists South
Fort Myers, Florida
SCRI Florida Cancer Specialists North
St. Petersburg, Florida
Advent Health Orlando
Winter Park, Florida
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana
Baptist Health Lexington
Lexington, Kentucky
Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Inova Schar Cancer Institute
Fairfax, Virginia
AZORG Campus Aalst-Moorselbaan
Aalst, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
CHU UCL Mont-Godinne
Mont-godinne, Belgium
Vitaz
Sint-Niklaas, Belgium
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Oncocentro Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, Canada
Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
Beijing Cancer Hospital
Beijing, China
Jilin Cancer Hospital
Changchun, China
Xiangya Hospital Central South University
Changsha, China
Affiliated Hospital of Chengde Medical University
Chengde, China
Sichuan Cancer Hospital
Chengdu, China
West China Hospital - Sichuan University
Chengdu, China
Anhui Provincial Hospital
Hefei, China
Jinan Central Hospital
Jinan, China
Pingxiang People's Hospital
Pingxiang, China
Qingdao Central Hospital
Qingdao, China
Weifang People's Hospital
Weifang, China
Hubei Cancer Hospital
Wuhan, China
The First Affiliated Hospital of Xian Jiao Tong University
Xi'an, China
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, China
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.